1. Home
  2. IR vs KVUE Comparison

IR vs KVUE Comparison

Compare IR & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ingersoll Rand Inc.

IR

Ingersoll Rand Inc.

HOLD

Current Price

$83.26

Market Cap

32.2B

Sector

Industrials

ML Signal

HOLD

Logo Kenvue Inc.

KVUE

Kenvue Inc.

HOLD

Current Price

$16.74

Market Cap

33.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
IR
KVUE
Founded
1859
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Specialty Chemicals
Sector
Industrials
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
32.2B
33.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
IR
KVUE
Price
$83.26
$16.74
Analyst Decision
Buy
Buy
Analyst Count
7
12
Target Price
$91.00
$20.00
AVG Volume (30 Days)
2.3M
32.8M
Earning Date
02-12-2026
02-05-2026
Dividend Yield
0.10%
4.93%
EPS Growth
N/A
35.31
EPS
1.35
0.75
Revenue
$7,458,300,000.00
$15,006,000,000.00
Revenue This Year
$8.07
N/A
Revenue Next Year
$4.48
$2.81
P/E Ratio
$60.80
$22.50
Revenue Growth
4.20
N/A
52 Week Low
$65.61
$14.02
52 Week High
$95.85
$25.17

Technical Indicators

Market Signals
Indicator
IR
KVUE
Relative Strength Index (RSI) 61.52 42.08
Support Level $78.65 $16.93
Resistance Level $81.82 $17.42
Average True Range (ATR) 1.67 0.22
MACD 0.12 -0.07
Stochastic Oscillator 94.64 0.66

Price Performance

Historical Comparison
IR
KVUE

About IR Ingersoll Rand Inc.

Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.2 billion in revenue in 2024.

About KVUE Kenvue Inc.

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.

Share on Social Networks: